Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in ECT for Mood and Cognition
NCT00566735Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2004
- Primary completion
- Jan 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of galantamine in major depressive disorder (MDD), bipolar disorder (BD), schizoaffective disorder, sponsored by Massachusetts General Hospital. Started Jul 2004; status: completed.
02
Drugs
galantamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)schizoaffective disorder
Beyond the preview
Go deeper on NCT00566735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566735.